TenNor Therapeutics, a Chinese biotech focused on anti-bacterial drugs, saw its shares jump 179% on debut in Hong Kong after an IPO oversubscribed 9,000 times. The company is developing rifasutenizol, a novel drug targeting Helicobacter pylori infections linked to stomach ulcers and gastric cancer, with approval expected by end of 2026. Despite cumulative losses over 490 million yuan, investors are betting on the drug's potential to address antibiotic resistance and capture a large market. The IPO raised about HK$598 million, supporting TenNor's late-stage clinical trials and future commercialization efforts.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Hi-View Resources Inc. has started its 2026 exploration program in the Toodoggone Mining District, British Columbia, focusing on porphyry targets at key sites like Lawyer’s East, Borealis, and Golden Stranger. The program includes 50 line kilometres ...
The U.S. Patent and Trademark Office (USPTO) has introduced an AI-assisted image search feature in its public trademark search system, TM Search, using technology from Clarivate Plc. This new tool allows users to upload images and compare them agains...
AIB Data Centers Inc. is considered a speculative buy with a $3.50 price target based on its 65 MW energized capacity. The investment case depends heavily on securing a single anchor lease at its CLT-01 facility, which would validate its business mod...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
